糖肾灵联合替米沙坦治疗早期糖尿病肾病的临床研究

作者	单位
李剑平	浙江大学医学院附属第一医院肾脏病中心
贺学林	浙江大学医学院附属第一医院肾脏病中心
李群	浙江大学医学院附属第一医院肾脏病中心
林维勤	浙江大学医学院附属第一医院肾脏病中心
孔静霞	浙江大学医学院附属第一医院肾脏病中心

摘要点击次数: 1151

全文下载次数: 3

中文摘要:

目的观察糖肾灵联合替米沙坦对早期糖尿病肾病(DN)的作用效果并研究其可能的机制。方法将81例早期DN患者随机分为对照组(40例)和治疗组(41例),对照组为常规西药和替米沙坦治疗,治疗组在此基础上加用糖肾灵。比较两组症状改善、尿白蛋白排泄率(UAER)、尿组织转化生长因子β1(TGF-β1)、尿视黄醇结合蛋白(RBP)和尿β2微球蛋白(β2-MG)、空腹血糖(FBG)、血肌酐、血脂、血浆心钠肽(ANP)、血Ⅳ型胶原(Col-Ⅳ)和TGF-β1水平的改变。结果两组在治疗前各项指标差异无显著性;经过8周的治疗后,治疗组各种症状改善率明显高于对照组(P<0·05或P<0·01);两组UAER、TC、TG、血Col-Ⅳ、血TGF-β1、尿RBP、尿β2-MG、尿TGF-β1和血压较治疗前均有明显下降(P<0·05或P<0·01),UAER、TC、TG、血Col-Ⅳ、血TGF-β1、尿RBP、尿β2-MG、尿TGF-β1治疗组较对照组下降更明显(P<0·05);FBG、SCr、血压治疗组较对照组稍低,但差异无显著性(P>0·05);治疗后治疗组血ANP较治疗前明显降低(P<0·01)。结论糖肾灵联合常规西药及替米沙坦治疗早期DN疗效比常规西药联用替米沙坦好,其机理可能与降低ANP、TGF-β1,改善脂质代谢和肾小管间质病变等有关。

英文摘要:

ObjectiveTo study the effects and the possible mechanism of Tangshenling （TSL） combined with telmisartan on early diabetic nephropathy （DN）. MethodsEighty-one patients with early DN were randomly assigned into the control group （n=40） treated by telmisartan alone and the treated group （n=41） treated by TSL combined with telmisartan, and the conventional western therapy was given to all patients in both groups. Changes before and after treatment in symptoms and levels of urine albumin excretion rate （UAER）, urine transforming growth factor β₁ （TGF-β₁）, retinol binding protein （RBP） and β₂-microglobulin （β₂-MG）, fasting blood glucose （FBG）, serum creatinine （SCr）, blood lipids, plasma atrial natriuretic peptide （ANP）, serum collagen type Ⅳ （Col-Ⅳ） and TGF-β₁ were observed. ResultsBefore treatment, no significant difference was shown in all these indexes between the treated group and the control group. After 8 weeks of treatment, the effective rates in symptoms improvement were higher in the treated group than those in the control group （P<0.05 or P<0.01）;UAER, urine RBP, β₂-MG and TGF-β₁, serum TC, TG, Col-Ⅳ and TGF-β₁, and blood pressure were significantly lowered in both groups after treatment （P<0.05 or P<0.01）; and the treated group showed a better effect than the control group in improving all the above-mentioned indexes except the blood pressure （P<0.05）; but there was no significant difference in the changes of FBG, SCr and blood pressure between the 2 groups （P>0.05）; after treatment, plasma ANP significantly lowered in the treated group （P<0.01）, while there was no significant change of that in the control group （P>0.05）. ConclusionCombination of TSL and telmisartan has a better effect than telmisartan on DN in early stage. Its mechanism might be related to the decrease of ANP and TGF-β₁ and improvement of lipids metabolism and renal tubular interstitial pathological changes.

关闭